Günther et al., 2015 - Google Patents
Functional autoantibodies in systemic sclerosisGünther et al., 2015
View PDF- Document ID
- 12771234292997109623
- Author
- Günther J
- Rademacher J
- van Laar J
- Siegert E
- Riemekasten G
- Publication year
- Publication venue
- Seminars in immunopathology
External Links
Snippet
Functional autoantibodies are an emerging field of research that focuses on the effects of these immunoglobulins when they bind to their target molecules. Accumulating information now exists about the molecular targets and precise binding mechanisms of functional …
- 206010042953 Systemic sclerosis 0 title abstract description 109
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Günther et al. | Functional autoantibodies in systemic sclerosis | |
US11359020B2 (en) | Agents that modulate immune cell activation and methods of use thereof | |
KR20180053682A (en) | Biomarkers related to interleukin-33 (IL-33) -mediated disease and uses thereof | |
Hak et al. | Dermatomyositis and polymyositis: new treatment targets on the horizon | |
CN111741752A (en) | GPCR heteromer inhibitors and uses thereof | |
Berger et al. | Role of anti-receptor autoantibodies in pathophysiology of scleroderma | |
KR102425676B1 (en) | T cell activation inhibitor, pharmaceutical composition containing same, and screening method for t cell activation inhibiting substance | |
JP6868655B2 (en) | Use of CD6 binding partners and methods based on them | |
US10648986B2 (en) | Method of identifying risk for thyroid disorder | |
EP1469879A1 (en) | Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders | |
KR20110018365A (en) | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists | |
JP2018506528A (en) | Therapeutic targets and biomarkers in IBD | |
US20170105971A1 (en) | Methods and compounds for the treatment of bone loss and/or pain | |
US20160159918A1 (en) | Methods for diagnosing and treating immune disease | |
Kempers et al. | Variable domain glycosylation of ACPA-IgG: A missing link in the maturation of the ACPA response? | |
CN113574071A (en) | anti-CD 38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody mediated autoimmune diseases | |
Sasaki-Iwaoka et al. | Generation and characterization of a potent fully human monoclonal antibody against the interleukin-23 receptor | |
JP2018506275A (en) | Gene expression markers and treatment of multiple sclerosis | |
US20190015397A1 (en) | Substance that inhibits p2y12 receptor, for use in the preventive treatment of systemic sclerosis in patients with raynaud's phenomenon and a dysimmunity | |
US20230295328A1 (en) | Treatment of idiopathic inflammatory myopathies | |
US20200405851A1 (en) | Method of diagnosis and treatment of rheumatoid arthritis | |
WO2017072494A1 (en) | Peptide and biomarker associated with inflammatory disorders, and uses thereof | |
JP2021097682A (en) | Therapy, diagnosis and screening using card14 | |
Stübgen | Targeted immunotherapy trials for idiopathic inflammatory myopathies | |
Tsui et al. | Evidence for an association between TSH and IGF-1 receptors: A tale of two antigens implicated in Graves’ disease1 |